growth more well believe forward, top XX% was bottom our past. by from in than growth revenues highlighted that historical our they solutions, growth rates you, performance to Plus Thank we have quarter exceeding the will above software Accordingly, growth. line continued Brian. Simulations XX%, quarter contribute consolidated The going XX% another with heavily and to rates. delivered strong of software
latter X we the XX% of in service high to Our decline. quarter, quarter. the view projects, service by and delays, the of holds an saw number factors, on service total, due development to which the unusually which overall program confident expansion several an project these impacted in was encountered leading all of or during and business drug decline we as during revenue disruptions, the impacted growth This pipeline near-term bookings Despite quarter. occurred solid business part backlog mid- to the long-term remain cancellations,
our our bottom faster than Given able evidenced grow top quarter. our we the the line, mix, strong software profitability strong to were by in as line
of results X our all exceeded expanding In accelerating the fact, growth business income revenues have we our and model inherent in net leverage reflect income total net our our XXXX. fiscal in months the through made software These for of margin. progress and profit our
interaction software As or rates this quarter, our pharmacokinetic, We XX%, DDI during drug-drug I upsells and added respectively. X was and XX module HTPK increase GastroPlus a or for solutions. strong with throughput customers demonstrating to growth XXX,XXX-plus club continued the license Predictor had mentioned, have of year continued to from last of the license the to high This and growth ADMET a to portfolio, quarter our renewals. and growth new with now our acquisition robust upsell. revenues as XX% outperform our up cross-sell our combined product of early is efforts and and anniversary due organic strength of expectations, Monolix demand the last with year. entirely revenue combination both X-year of we to passed XXX%
during a market. in new of quarter, training addressable China expanding the distributor the completed our also We significantly
deeper cross-selling paying opportunity customers. by and Our our relationship and business increasing pipeline development creating investments are a off with sales
selection, Predictor, to enhance for better and We release improved new a overall and enhanced our accuracy, latest extend capabilities with and ADMET experience. allow user which lead also industry performance continue automation add position the leadership will of
quarter, fourth is Suite newest in by the the on for calendar of year-end. track the Monolix is Additionally, version target and on [GPxXX] release release for
Turning service to offerings. our
and service volatility. of nonrecurring some revenue can, is exhibit therefore, measure Our
and to encountered largely our and into quarter, or $XXX,XXX the and drug revenue do cancel to new But customer environment, programs the aggressive We in are see this the QSP/QST development projects changes are our forward by development from pandemic this to mix fourth services projects cancellations. out to and delayed PK/PD significant in impacted we offset been delays project $XXX,XXX quarter, projects that revenue by have quarter. or continue program that several so our disruptions range. backlog. typically pulled accelerate projects the will During Customers are several of delays quicker growth. time saw control. drug meet Historically, impacted PK/PD lines issues challenging the
whether customers allows compound. or on of contribute service an to decisions not industry the our and make this technology development project with to fast can quickly Fail objective, more volatility. to is proceed Our
with a COVID impact. on projects saw tail as often delays sourced in quarter of end are from of the research compound. FDA service projects latter, to respect specific initiated requesting We With past into also the from the the as Israel based elements feedback this well more
time the as as of clinical has for trial submitted has and the FDA disruptive, to and the During drugs this time. line well workflow FDA somewhat normal impacted to the the for be schedule been pandemic, regulators reviews FDA and with certain other the
these somewhat Since saw large quarter. we the many and number COVID cycle late sales during changes elongated of our came already. in had As a notifications a of result, been
were at the resources the our the reallocate Our ability note, this the despite bookings backfill approximately increased for of service good. On backlog to typical projects by not X% these business, and levels cancellation. And positive make limiting up changes. a for to during was quarter backlog our
X which optimism. quarter, reinforces also We clients the our added new during
had tend a regulators that fiscal this and sponsor On are to higher-than-normal capabilities that to a side, concluded in very larger late these have making dollars, large revenue Further, the be when provide projects of smaller of projects driving in the X this area. we standard result in work liver the feedback terms QSP/QST gold QSP/QST of compound potential want more on FDA toxicology additional XXXX, from volatile. revenue. usually for projects data issues with the the
to continues rearview think the development pipeline overall COVID will pharma normalize. As we mirror,
see opportunities Separately, sales That did normal the in backlog furthering integration remains in and opportunities. to pipeline larger leaders. our will said, industry with large, significant model convert ultimately, an than additional our consortium We add fact, we liver to revenue. the member quarter, with
operating Finally, but results challenging than the solid show. Overall, service services our regulatory the the and more quarter this in reported are PBPK quarter encouraging capacity. for resources services division, our our are at trends performance
is projects -- project-based to The result nature these healthy robust overperformance Our and services in demand of growing. enjoy periods sales continue and periods some of revenues underperformance. some of our pipeline and
our for services executions revenue, revenue market quarter to its growth outlook to to exposure full in And volatility encountered service for outlook revenue fluctuations is long-term Our we the minimize service adoption the we Based revenue growth. slowdown to and change long in total contribute or our run on and a disruption of overall not remains The company. are the expecting this business year our as growth to our in our improve the with business, accelerating profitability. XX%. modeling continue reflective growth services prospects unchanged simulations ability that now X% of software of any
that revenue 'XX account guidance holds to XX%. see the in projects. XX% means timing will don't was lower are over forward. when projects a decline grow grow we we and have that that year and accelerated to drug customer in see annually. by revenue we to the fourth third to due XX% quarter revenue as move the growth into of fiscal delays, XXXX likely we're QX full to and fiscal were software related than expect situation year will This visibility year. our to yet down year to the this XX% development anticipated the renewals expecting temporary program the While guidance, year-to-date more longer we X%, X% for timing Breaking full Again, yet view of and our the these releasing fiscal of predict to not we takes is Year-to-date, XX% service revenues, strictly we The full necessary cancellations the down, services term quarter. our flat Monolix believe
Will our Let to me call to now results. discuss financial Frederick, the CFO, turn the